These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25339302)

  • 1. Medullary carcinoma of the colon: can the undifferentiated be differentiated?
    Fiehn AM; Grauslund M; Glenthøj A; Melchior LC; Vainer B; Willemoe GL
    Virchows Arch; 2015 Jan; 466(1):13-20. PubMed ID: 25339302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.
    Winn B; Tavares R; Fanion J; Noble L; Gao J; Sabo E; Resnick MB
    Hum Pathol; 2009 Mar; 40(3):398-404. PubMed ID: 18992917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic mechanisms in interval colon cancers.
    Richter JM; Pino MS; Austin TR; Campbell E; Szymonifka J; Russo AL; Hong TS; Borger D; Iafrate AJ; Chung DC
    Dig Dis Sci; 2014 Sep; 59(9):2255-63. PubMed ID: 24705641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
    Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
    Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition.
    Gurzu S; Szentirmay Z; Toth E; Bara T; Bara T; Jung I
    PLoS One; 2013; 8(3):e57699. PubMed ID: 23469219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report.
    El Agy F; El Bardai S; El Otmani I; Benbrahim Z; Karim MH; Mazaz K; Benjelloun EB; Ousadden A; El Abkari M; Ibrahimi SA; Chbani L
    PLoS One; 2021; 16(3):e0248522. PubMed ID: 33784337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.
    Revuelta I; Moya-Rull D; García-Herrera A; Rovira J; Ayala de la Peña F; Misiego A; Guzmán F; Oppenheimer F; Albanell J; Campistol JM
    Transplantation; 2012 Mar; 93(5):509-17. PubMed ID: 22245873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.
    Soliman ML; Tiwari A; Zhao Q
    World J Gastroenterol; 2017 Feb; 23(6):1106-1112. PubMed ID: 28246485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma].
    Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine.
    Lin F; Shi J; Zhu S; Chen Z; Li A; Chen T; Wang HL; Liu H
    Arch Pathol Lab Med; 2014 Aug; 138(8):1015-26. PubMed ID: 24437456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
    Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
    Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive study of nondysplastic and dysplastic serrated polyps of the vermiform appendix.
    Yantiss RK; Panczykowski A; Misdraji J; Hahn HP; Odze RD; Rennert H; Chen YT
    Am J Surg Pathol; 2007 Nov; 31(11):1742-53. PubMed ID: 18059232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serrated adenoma of the stomach: a clinicopathologic, immunohistochemical, and molecular study of nine cases.
    Kwon MJ; Min BH; Lee SM; Park HY; Kang SY; Ha SY; Lee JH; Kim JJ; Park CK; Kim KM
    Histol Histopathol; 2013 Apr; 28(4):453-62. PubMed ID: 23404616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer.
    Sanchez JA; Dejulius KL; Bronner M; Church JM; Kalady MF
    Inflamm Bowel Dis; 2011 Sep; 17(9):1966-70. PubMed ID: 21618350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
    Di Bartolomeo M; Pietrantonio F; Perrone F; Dotti KF; Lampis A; Bertan C; Beretta E; Rimassa L; Carbone C; Biondani P; Passalacqua R; Pilotti S; Bajetta E;
    Target Oncol; 2014 Jun; 9(2):155-62. PubMed ID: 23821376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.